LYSOCLEAR has been extensively studied in buffer systems, cell culture models, and in vivo.
LYSOCLEAR is safe and effective at breaking down toxic A2E, removing up to 10% with each dose.
LYSOCLEAR selectively localizes to the lysosomes of RPE cells where A2E accumulates, and destroys it.
As a practicing ophthalmologist, it is heartbreaking to see my patients lose vision at any age -- old or young. There is a desperate need for new, effective drugs to treat vision loss. LYSOCLEAR holds great promise to help my patients with macular degeneration, both juvenile onset and age-related.
William Tucker, MD
The idea of upgrading lysosomes of cells with the ability to degrade age-associated molecular garbage could fundamentally change how we think about and treat numerous age-related diseases. LYSOCLEAR targeting A2E in macular degeneration is an excellent proof-of-concept for an entirely new field: enzyme augmentation therapy,
Aubrey de Grey, PhD